Vaccines for children and adults with chronic lung disease

Efficacy against acute exacerbations

Kerry-Ann O'Grady, Anne Chang, Keith Grimwood

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Acute exacerbations of chronic lung disease are usually associated with viral and bacterial pathogens. They contribute to declining lung function, poor quality of life and exert an excess burden on individuals, families, communities and the healthcare sector. Hence, preventing exacerbations is important in clinical management. Several vaccines providing protection against respiratory pathogens (Streptococcus pneumoniae, Bordetella pertussis and influenza) that can trigger exacerbations are available, but evidence to support their effectiveness in preventing exacerbations of chronic lung disease is limited. Candidate vaccines in pre-clinical or clinical development phases include those targeting Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, respiratory syncytial virus and human rhinoviruses. However, it is likely to be several years before vaccines against these pathogens are available for children and adults with chronic lung diseases. For vaccination to play an important role in managing chronic lung disease efforts need to be directed at understanding how various pathogens cause exacerbations and alter long-term lung function.
Original languageEnglish
Pages (from-to)43-55
Number of pages13
JournalExpert Review of Respiratory Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Lung Diseases
Chronic Disease
Vaccines
Human respiratory syncytial virus
Moraxella (Branhamella) catarrhalis
Rhinovirus
Community Health Services
Bordetella pertussis
Lung
Health Care Sector
Haemophilus influenzae
Streptococcus pneumoniae
Pseudomonas aeruginosa
Human Influenza
Staphylococcus aureus
Vaccination
Quality of Life

Cite this

@article{9ae65525cf79460da3ba4da76df9d369,
title = "Vaccines for children and adults with chronic lung disease: Efficacy against acute exacerbations",
abstract = "Acute exacerbations of chronic lung disease are usually associated with viral and bacterial pathogens. They contribute to declining lung function, poor quality of life and exert an excess burden on individuals, families, communities and the healthcare sector. Hence, preventing exacerbations is important in clinical management. Several vaccines providing protection against respiratory pathogens (Streptococcus pneumoniae, Bordetella pertussis and influenza) that can trigger exacerbations are available, but evidence to support their effectiveness in preventing exacerbations of chronic lung disease is limited. Candidate vaccines in pre-clinical or clinical development phases include those targeting Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, respiratory syncytial virus and human rhinoviruses. However, it is likely to be several years before vaccines against these pathogens are available for children and adults with chronic lung diseases. For vaccination to play an important role in managing chronic lung disease efforts need to be directed at understanding how various pathogens cause exacerbations and alter long-term lung function.",
keywords = "influenza vaccine, Pneumococcus vaccine, adult disease, Bordetella pertussis, childhood disease, chronic lung disease, disease exacerbation, drug efficacy, Haemophilus influenzae, human, Human rhinovirus, influenza A, influenza B, influenza C, lung function, Moraxella catarrhalis, Pseudomonas aeruginosa, quality of life, Respiratory syncytial pneumovirus, review, Staphylococcus aureus, Streptococcus pneumoniae, vaccination, Adult, Bacterial Vaccines, Child, Chronic Disease, Humans, Influenza Vaccines, Lung Diseases, Pneumococcal Vaccines, Treatment Outcome, Viral Vaccines",
author = "Kerry-Ann O'Grady and Anne Chang and Keith Grimwood",
year = "2014",
doi = "10.1586/17476348.2014.852960",
language = "English",
volume = "8",
pages = "43--55",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews",
number = "1",

}

Vaccines for children and adults with chronic lung disease : Efficacy against acute exacerbations. / O'Grady, Kerry-Ann; Chang, Anne; Grimwood, Keith.

In: Expert Review of Respiratory Medicine, Vol. 8, No. 1, 2014, p. 43-55.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Vaccines for children and adults with chronic lung disease

T2 - Efficacy against acute exacerbations

AU - O'Grady, Kerry-Ann

AU - Chang, Anne

AU - Grimwood, Keith

PY - 2014

Y1 - 2014

N2 - Acute exacerbations of chronic lung disease are usually associated with viral and bacterial pathogens. They contribute to declining lung function, poor quality of life and exert an excess burden on individuals, families, communities and the healthcare sector. Hence, preventing exacerbations is important in clinical management. Several vaccines providing protection against respiratory pathogens (Streptococcus pneumoniae, Bordetella pertussis and influenza) that can trigger exacerbations are available, but evidence to support their effectiveness in preventing exacerbations of chronic lung disease is limited. Candidate vaccines in pre-clinical or clinical development phases include those targeting Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, respiratory syncytial virus and human rhinoviruses. However, it is likely to be several years before vaccines against these pathogens are available for children and adults with chronic lung diseases. For vaccination to play an important role in managing chronic lung disease efforts need to be directed at understanding how various pathogens cause exacerbations and alter long-term lung function.

AB - Acute exacerbations of chronic lung disease are usually associated with viral and bacterial pathogens. They contribute to declining lung function, poor quality of life and exert an excess burden on individuals, families, communities and the healthcare sector. Hence, preventing exacerbations is important in clinical management. Several vaccines providing protection against respiratory pathogens (Streptococcus pneumoniae, Bordetella pertussis and influenza) that can trigger exacerbations are available, but evidence to support their effectiveness in preventing exacerbations of chronic lung disease is limited. Candidate vaccines in pre-clinical or clinical development phases include those targeting Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, respiratory syncytial virus and human rhinoviruses. However, it is likely to be several years before vaccines against these pathogens are available for children and adults with chronic lung diseases. For vaccination to play an important role in managing chronic lung disease efforts need to be directed at understanding how various pathogens cause exacerbations and alter long-term lung function.

KW - influenza vaccine

KW - Pneumococcus vaccine

KW - adult disease

KW - Bordetella pertussis

KW - childhood disease

KW - chronic lung disease

KW - disease exacerbation

KW - drug efficacy

KW - Haemophilus influenzae

KW - human

KW - Human rhinovirus

KW - influenza A

KW - influenza B

KW - influenza C

KW - lung function

KW - Moraxella catarrhalis

KW - Pseudomonas aeruginosa

KW - quality of life

KW - Respiratory syncytial pneumovirus

KW - review

KW - Staphylococcus aureus

KW - Streptococcus pneumoniae

KW - vaccination

KW - Adult

KW - Bacterial Vaccines

KW - Child

KW - Chronic Disease

KW - Humans

KW - Influenza Vaccines

KW - Lung Diseases

KW - Pneumococcal Vaccines

KW - Treatment Outcome

KW - Viral Vaccines

UR - http://informahealthcare.com/doi/abs/10.1586/17476348.2014.852960

U2 - 10.1586/17476348.2014.852960

DO - 10.1586/17476348.2014.852960

M3 - Article

VL - 8

SP - 43

EP - 55

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 1

ER -